(firstQuint)A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE).

 This is a phase 1, randomized, double-blind, placebo-controlled, single-and multiple ascending dose study.

 Up to eighty-eight subjects with Systemic Lupus Erythematosus will be selected to participate.

 Subjects will be randomized to receive either ABT-199 or placebo.

 Subjects will be administered ABT-199/placebo as a single dose or up to 14 days as multiple doses.

.

 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)@highlight

To assess the safety, tolerability and pharmacokinetics of ABT-199 in female subjects with Systemic Lupus Erythematosus.

